Shots:

• The companies collaborated to assess recombinant protein-based COVID-19 XWG-03- being developed by Innovax with Xiamen University
• GSK will provide Innovax access to its adjuvant system for preclinical evaluation of the COVID-19 XWG-03. GSK’s adjuvants are additives used in vaccines to boost the body's immune response to the relevant threat
• The COVID-19 XWG-03 is based on a series of truncated S (spike) proteins which will be screened during the pre-clinical testing and a lead candidate will be determined based on its immunogenicity. Additionally- in 2019- the companies collaborated to develop a vaccine for HPV to devise a successor to Cervarix

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK